Dec 17, 2024 8:00am EST Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia
Dec 9, 2024 7:30am EST Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers
Dec 3, 2024 7:00am EST Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires
Nov 18, 2024 7:00am EST Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting
Nov 13, 2024 4:05pm EST Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting
Nov 13, 2024 9:05am EST Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company’s Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals
Nov 12, 2024 8:00am EST Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights
Nov 4, 2024 7:00am EST Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya
